Background: Numerous oncology patients who receive targeted therapy suffer from the skin adverse effects induced. Novel agents, that is tyrosine kinase inhibitors and RAS-RAF-MEK-ERK pathway, have given good results in patient survival while decreasing the systemic toxicities in comparison to conventional cytotoxic chemotherapy, but are also related to skin adverse effects.
Aims: In this article, we highlighted the importance of specific pharmaceutical and dermocosmetic management of the untoward events of targeted therapy.
Conclusion: The combination of Oncodermatology, Psychodermatology, Cosmetic Dermatology, Cosmetic Science, Dermatopharmacology and Aesthetic Science can offer a lot for the prevention or early relief of the cutaneous adverse effects in oncology patients receiving targeted therapy.
Keywords: cosmetics; dermocosmetic management; oncology; pharmaceuticals; skin adverse effects.
© 2019 Wiley Periodicals, Inc.